Group 1 - The core viewpoint of the article highlights that Weili Medical (603309) has seen a stock price increase of 4.18%, closing at 14.94 yuan as of February 6, 2026, compared to 14.34 yuan the previous week [1] - The company achieved a total market capitalization of 4.361 billion yuan, ranking 88th out of 129 in the medical device sector and 3870th out of 5186 in the A-share market [1] - The highest intraday price recorded for Weili Medical during the week was 14.99 yuan, while the lowest was 13.85 yuan [1] Group 2 - Weili Medical announced that multiple products have received EU MDR certification, allowing them to be sold in the European market [1] - The certified products include a range of medical devices such as urinary catheter care kits, drainage bags, puncture guides, and various types of catheters and tubes [1] - The certification was issued by TÜV SÜD Product Service GmbH, with a validity period until May 15, 2028, or December 5, 2028, confirming compliance with the latest EU medical device regulations [1]

Group 1 - The core point of the article is that Weili Medical has received EU MDR certification for multiple products, allowing them to be legally sold in the EU market [1][3]. - On February 5, 2026, Weili Medical's stock closed at 14.57 yuan, with an increase of 1.25% and a trading volume of 52,200 shares, amounting to a total transaction value of 75.83 million yuan [1]. - The net capital flow on February 5 shows a net outflow of 324,100 yuan from main funds, while retail funds experienced a net outflow of 46,400 yuan [1][3]. Group 2 - The products that received EU MDR certification include urinary catheter care kits, drainage bags, puncture guides, nebulizers, and various other medical devices [1]. - The certification was issued by TÜV SÜD Product Service GmbH, with a validity period until May 15, 2028, or December 5, 2028 [1].